Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 5
2004 5
2005 5
2006 7
2007 2
2008 2
2009 7
2010 3
2011 3
2012 7
2013 1
2014 6
2015 3
2016 7
2017 3
2018 8
2019 7
2020 8
2021 5
2022 4
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Results by year

Filters applied: . Clear all
Page 1
Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors.
Muraro E, Montico B, Lum B, Colizzi F, Giurato G, Salvati A, Guerrieri R, Rizzo A, Comaro E, Canzonieri V, Anichini A, Del Vecchio M, Mortarini R, Milione M, Weisz A, Pizzichetta MA, Simpson F, Dolcetti R, Fratta E, Sigalotti L. Muraro E, et al. Among authors: anichini a. Front Immunol. 2024 Mar 6;15:1336566. doi: 10.3389/fimmu.2024.1336566. eCollection 2024. Front Immunol. 2024. PMID: 38510242 Free PMC article.
Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches.
Lofiego MF, Piazzini F, Caruso FP, Marzani F, Solmonese L, Bello E, Celesti F, Costa MC, Noviello T, Mortarini R, Anichini A, Ceccarelli M, Coral S, Di Giacomo AM, Maio M, Covre A; EPigenetic Immune-oncology Consortium Airc (EPICA) investigators. Lofiego MF, et al. Among authors: anichini a. J Transl Med. 2024 Mar 1;22(1):223. doi: 10.1186/s12967-024-05040-x. J Transl Med. 2024. PMID: 38429759 Free PMC article.
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.
Noviello TMR, Di Giacomo AM, Caruso FP, Covre A, Mortarini R, Scala G, Costa MC, Coral S, Fridman WH, Sautès-Fridman C, Brich S, Pruneri G, Simonetti E, Lofiego MF, Tufano R, Bedognetti D, Anichini A, Maio M, Ceccarelli M. Noviello TMR, et al. Among authors: anichini a. Nat Commun. 2023 Sep 22;14(1):5914. doi: 10.1038/s41467-023-40994-4. Nat Commun. 2023. PMID: 37739939 Free PMC article. Clinical Trial.
Gut Microbiota, Metabolome, and Body Composition Signatures of Response to Therapy in Patients with Advanced Melanoma.
Vandoni G, D'Amico F, Fabbrini M, Mariani L, Sieri S, Casirati A, Di Guardo L, Del Vecchio M, Anichini A, Mortarini R, Sgambelluri F, Celano G, Serale N, De Angelis M, Brigidi P, Gavazzi C, Turroni S. Vandoni G, et al. Among authors: anichini a. Int J Mol Sci. 2023 Jul 18;24(14):11611. doi: 10.3390/ijms241411611. Int J Mol Sci. 2023. PMID: 37511376 Free PMC article.
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis.
Lo Russo G, Prelaj A, Dolezal J, Beninato T, Agnelli L, Triulzi T, Fabbri A, Lorenzini D, Ferrara R, Brambilla M, Occhipinti M, Mazzeo L, Provenzano L, Spagnoletti A, Viscardi G, Sgambelluri F, Brich S, Miskovic V, Pedrocchi ALG, Trovo' F, Manglaviti S, Giani C, Ambrosini P, Leporati R, Franza A, McCulloch J, Torelli T, Anichini A, Mortarini R, Trinchieri G, Pruneri G, Torri V, De Braud F, Proto C, Ganzinelli M, Garassino MC. Lo Russo G, et al. Among authors: anichini a. J Immunother Cancer. 2023 Jun;11(6):e006833. doi: 10.1136/jitc-2023-006833. J Immunother Cancer. 2023. PMID: 37286305 Free PMC article. Clinical Trial.
Immunotherapy for brain metastases and primary brain tumors.
Di Giacomo AM, Mair MJ, Ceccarelli M, Anichini A, Ibrahim R, Weller M, Lahn M, Eggermont AMM, Fox B, Maio M. Di Giacomo AM, et al. Among authors: anichini a. Eur J Cancer. 2023 Jan;179:113-120. doi: 10.1016/j.ejca.2022.11.012. Epub 2022 Nov 24. Eur J Cancer. 2023. PMID: 36521332
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy.
Anichini A, Molla A, Nicolini G, Perotti VE, Sgambelluri F, Covre A, Fazio C, Lofiego MF, Di Giacomo AM, Coral S, Manca A, Sini MC, Pisano M, Noviello T, Caruso F, Brich S, Pruneri G, Maurichi A, Santinami M, Ceccarelli M, Palmieri G, Maio M, Mortarini R; EPigenetic Immune-oncology Consortium AIRC (EPICA) investigators. Anichini A, et al. J Exp Clin Cancer Res. 2022 Nov 17;41(1):325. doi: 10.1186/s13046-022-02529-5. J Exp Clin Cancer Res. 2022. PMID: 36397155 Free PMC article.
A novel microRNA signature for the detection of melanoma by liquid biopsy.
Sabato C, Noviello TMR, Covre A, Coral S, Caruso FP, Besharat ZM, Splendiani E, Masuelli L, Battistelli C, Vacca A, Catanzaro G, Po A, Anichini A, Maio M, Ceccarelli M, Di Giacomo AM, Ferretti E. Sabato C, et al. Among authors: anichini a. J Transl Med. 2022 Oct 15;20(1):469. doi: 10.1186/s12967-022-03668-1. J Transl Med. 2022. PMID: 36243798 Free PMC article.
A microRNA Prognostic Signature in Patients with Diffuse Intrinsic Pontine Gliomas through Non-Invasive Liquid Biopsy.
Iannó MF, Biassoni V, Schiavello E, Carenzo A, Boschetti L, Gandola L, Diletto B, Marchesi E, Vegetti C, Molla A, Kramm CM, van Vuurden DG, Gasparini P, Gianno F, Giangaspero F, Modena P, Bison B, Anichini A, Vennarini S, Pignoli E, Massimino M, De Cecco L. Iannó MF, et al. Among authors: anichini a. Cancers (Basel). 2022 Sep 2;14(17):4307. doi: 10.3390/cancers14174307. Cancers (Basel). 2022. PMID: 36077842 Free PMC article.
99 results